Table 1.
Patients’ characteristics.
| Recurrence |
No recurrence |
p | |||
|---|---|---|---|---|---|
| n = 42 | % | N = 42 | % | ||
| Age median (range) | 54 (32–79) | 53 (30–78) | 0.88 | ||
| FIGO stage | |||||
| IB1 | 2 | 5 | 2 | 5 | 0.62 |
| IB2 | 2 | 5 | 2 | 5 | 0.62 |
| IIA | 2 | 5 | 2 | 5 | 0.62 |
| IIB | 24 | 57 | 24 | 57 | 0.83 |
| IIIA | 2 | 5 | 2 | 5 | 0.62 |
| IIIB | 6 | 14 | 6 | 14 | 0.75 |
| IVA | 4 | 9 | 4 | 9 | 0.70 |
| Histology | |||||
| Squamous carcinoma | 34 | 81 | 34 | 81 | 0.78 |
| Adenocarcinoma | 6 | 14 | 6 | 14 | 0.75 |
| Adenosquamous carcinoma | 0 | 0 | 0 | 0 | |
| Clear cell carcinoma | 2 | 5 | 2 | 5 | 0.62 |
| Grade | |||||
| I | 16 | 38 | 16 | 38 | 0.82 |
| II | 16 | 38 | 17 | 41 | 0.95 |
| III | 10 | 24 | 9 | 21 | 0.95 |
| Lymph node involvement | |||||
| Uninvoled | 18 | 43 | 18 | 43 | 0.83 |
| Involved | 24 | 57 | 24 | 57 | 0.83 |
| pelvic | 16 | 67 | 16 | 67 | 0.76 |
| pelvic and para-aortic | 8 | 33 | 8 | 33 | 0.76 |
| V1 (mean ± STD) | 14.8 ± 10.6 cm3 | 14.4 ± 10.2 cm3 | 0.86 | ||
| MTV (mean ± STD) | 42.6 ± 32.1 cm3 | 38.0 ± 22.9 cm3 | 0.45 | ||
| SUVmax (mean ± STD) | 19.9 ± 8.1 | 19.4 ± 7.5 | 0.77 | ||
| Treatment | |||||
| 3D-CRT | 30 | 71 | 30 | 71 | 0.81 |
| IMRT | 12 | 29 | 12 | 29 | 0.81 |
| EBRT dose median (range) | 45 (45–54) | 45 (45–54) | 1.00 | ||
| BT dose median (range) | 24 (21–26) | 24 (21–26) | 1.00 | ||
| D98 GTV res median (range) | 99.6 (93.1–102.5) | 99.5 (92.8–102.3) | 0.95 | ||
Abbreviations: FIGO = International Federation of Gynecology and Obstetrics, V1: high-uptake sub-volumes, MTV: metabolic tumor volume, TLG: total lesion glycolysis, 3D-RT = three-dimensional conformal radiotherapy, IMRT = intensity-modulated photon radiotherapy, EBRT = external beam radiotherapy, BT = brachytherapy, D98 GTV res: dose of 98Gya/b = 10 to the Residual Gross Tumour Volume of the primary Tumour.